MDACC Study No:2009-0419 ( NCT No: NCT00908752)
Title:A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study (CA182037)
Principal Investigator:Ahmed Kaseb
Treatment Agent:Brivanib; TACE
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if adding brivanib to the
TACE procedure can affect survival in patients with liver cancer. The safety
of brivanib will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Liver
Phase of Study:Phase III
Treatment Agents:Brivanib
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:NA
Supported By:BMS
Return Visit:Every week for the first month. Once a month thereafter.
Home Care:NA

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Ahmed Kaseb
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-745-5517
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults